Cargando…

A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome

To investigate long COVID-19 syndrome (LCS) pathophysiology, we performed an exploratory study with blood plasma derived from three groups: 1) healthy vaccinated individuals without SARS-CoV-2 exposure; 2) asymptomatic recovered patients at least three months after SARS-CoV-2 infection and; 3) sympt...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovarik, Johannes J., Bileck, Andrea, Hagn, Gerhard, Meier-Menches, Samuel M., Frey, Tobias, Kaempf, Anna, Hollenstein, Marlene, Shoumariyeh, Tarik, Skos, Lukas, Reiter, Birgit, Gerner, Marlene C., Spannbauer, Andreas, Hasimbegovic, Ena, Schmidl, Doreen, Garhöfer, Gerhard, Gyöngyösi, Mariann, Schmetterer, Klaus G., Gerner, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719844/
https://www.ncbi.nlm.nih.gov/pubmed/36507225
http://dx.doi.org/10.1016/j.isci.2022.105717
_version_ 1784843415854252032
author Kovarik, Johannes J.
Bileck, Andrea
Hagn, Gerhard
Meier-Menches, Samuel M.
Frey, Tobias
Kaempf, Anna
Hollenstein, Marlene
Shoumariyeh, Tarik
Skos, Lukas
Reiter, Birgit
Gerner, Marlene C.
Spannbauer, Andreas
Hasimbegovic, Ena
Schmidl, Doreen
Garhöfer, Gerhard
Gyöngyösi, Mariann
Schmetterer, Klaus G.
Gerner, Christopher
author_facet Kovarik, Johannes J.
Bileck, Andrea
Hagn, Gerhard
Meier-Menches, Samuel M.
Frey, Tobias
Kaempf, Anna
Hollenstein, Marlene
Shoumariyeh, Tarik
Skos, Lukas
Reiter, Birgit
Gerner, Marlene C.
Spannbauer, Andreas
Hasimbegovic, Ena
Schmidl, Doreen
Garhöfer, Gerhard
Gyöngyösi, Mariann
Schmetterer, Klaus G.
Gerner, Christopher
author_sort Kovarik, Johannes J.
collection PubMed
description To investigate long COVID-19 syndrome (LCS) pathophysiology, we performed an exploratory study with blood plasma derived from three groups: 1) healthy vaccinated individuals without SARS-CoV-2 exposure; 2) asymptomatic recovered patients at least three months after SARS-CoV-2 infection and; 3) symptomatic patients at least 3 months after SARS-CoV-2 infection with chronic fatigue syndrome or similar symptoms, here designated as patients with long COVID-19 syndrome (LCS). Multiplex cytokine profiling indicated slightly elevated pro-inflammatory cytokine levels in recovered individuals in contrast to patients with LCS. Plasma proteomics demonstrated low levels of acute phase proteins and macrophage-derived secreted proteins in LCS. High levels of anti-inflammatory oxylipins including omega-3 fatty acids in LCS were detected by eicosadomics, whereas targeted metabolic profiling indicated high levels of anti-inflammatory osmolytes taurine and hypaphorine, but low amino acid and triglyceride levels and deregulated acylcarnitines. A model considering alternatively polarized macrophages as a major contributor to these molecular alterations is presented.
format Online
Article
Text
id pubmed-9719844
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97198442022-12-05 A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome Kovarik, Johannes J. Bileck, Andrea Hagn, Gerhard Meier-Menches, Samuel M. Frey, Tobias Kaempf, Anna Hollenstein, Marlene Shoumariyeh, Tarik Skos, Lukas Reiter, Birgit Gerner, Marlene C. Spannbauer, Andreas Hasimbegovic, Ena Schmidl, Doreen Garhöfer, Gerhard Gyöngyösi, Mariann Schmetterer, Klaus G. Gerner, Christopher iScience Article To investigate long COVID-19 syndrome (LCS) pathophysiology, we performed an exploratory study with blood plasma derived from three groups: 1) healthy vaccinated individuals without SARS-CoV-2 exposure; 2) asymptomatic recovered patients at least three months after SARS-CoV-2 infection and; 3) symptomatic patients at least 3 months after SARS-CoV-2 infection with chronic fatigue syndrome or similar symptoms, here designated as patients with long COVID-19 syndrome (LCS). Multiplex cytokine profiling indicated slightly elevated pro-inflammatory cytokine levels in recovered individuals in contrast to patients with LCS. Plasma proteomics demonstrated low levels of acute phase proteins and macrophage-derived secreted proteins in LCS. High levels of anti-inflammatory oxylipins including omega-3 fatty acids in LCS were detected by eicosadomics, whereas targeted metabolic profiling indicated high levels of anti-inflammatory osmolytes taurine and hypaphorine, but low amino acid and triglyceride levels and deregulated acylcarnitines. A model considering alternatively polarized macrophages as a major contributor to these molecular alterations is presented. Elsevier 2022-12-05 /pmc/articles/PMC9719844/ /pubmed/36507225 http://dx.doi.org/10.1016/j.isci.2022.105717 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kovarik, Johannes J.
Bileck, Andrea
Hagn, Gerhard
Meier-Menches, Samuel M.
Frey, Tobias
Kaempf, Anna
Hollenstein, Marlene
Shoumariyeh, Tarik
Skos, Lukas
Reiter, Birgit
Gerner, Marlene C.
Spannbauer, Andreas
Hasimbegovic, Ena
Schmidl, Doreen
Garhöfer, Gerhard
Gyöngyösi, Mariann
Schmetterer, Klaus G.
Gerner, Christopher
A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome
title A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome
title_full A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome
title_fullStr A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome
title_full_unstemmed A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome
title_short A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome
title_sort multi-omics based anti-inflammatory immune signature characterizes long covid-19 syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719844/
https://www.ncbi.nlm.nih.gov/pubmed/36507225
http://dx.doi.org/10.1016/j.isci.2022.105717
work_keys_str_mv AT kovarikjohannesj amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT bileckandrea amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT hagngerhard amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT meiermenchessamuelm amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT freytobias amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT kaempfanna amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT hollensteinmarlene amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT shoumariyehtarik amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT skoslukas amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT reiterbirgit amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT gernermarlenec amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT spannbauerandreas amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT hasimbegovicena amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT schmidldoreen amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT garhofergerhard amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT gyongyosimariann amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT schmettererklausg amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT gernerchristopher amultiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT kovarikjohannesj multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT bileckandrea multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT hagngerhard multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT meiermenchessamuelm multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT freytobias multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT kaempfanna multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT hollensteinmarlene multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT shoumariyehtarik multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT skoslukas multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT reiterbirgit multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT gernermarlenec multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT spannbauerandreas multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT hasimbegovicena multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT schmidldoreen multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT garhofergerhard multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT gyongyosimariann multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT schmettererklausg multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome
AT gernerchristopher multiomicsbasedantiinflammatoryimmunesignaturecharacterizeslongcovid19syndrome